<div id="readability-page-1"><p>Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Leah Neufeld bought 2,626 shares of the firm's stock in a transaction dated Tuesday, January 13th. The shares were acquired at an average price of $4.15 per share, for a total transaction of $10,897.90. Following the completion of the transaction, the insider owned 25,970 shares in the company, valued at $107,775.50. This represents a 11.25% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.</p><h2>Immuneering Trading Up 4.0%</h2><p>NASDAQ:IMRX traded up $0.18 during mid-day trading on Thursday, hitting $4.61. The company's stock had a trading volume of 679,229 shares, compared to its average volume of 4,423,273. The company has a market capitalization of $297.34 million, a price-to-earnings ratio of -2.59 and a beta of 0.48. Immuneering Corporation has a fifty-two week low of $1.10 and a fifty-two week high of $10.08. The stock has a fifty day moving average of $6.45 and a 200-day moving average of $5.78. </p><p>Immuneering (NASDAQ:IMRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01).  On average, equities analysts anticipate that  Immuneering Corporation will post -1.86 earnings per share for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><p>Several equities research analysts have recently weighed in on the stock. Leerink Partners began coverage on shares of Immuneering in a research report on Friday, October 31st. They set an &#34;outperform&#34; rating and a $15.00 target price for the company. Wall Street Zen lowered shares of Immuneering from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, December 20th. HC Wainwright  reiterated a &#34;buy&#34; rating and issued a $11.00 target price on shares of Immuneering in a research note on Tuesday, September 30th. Leerink Partnrs upgraded Immuneering to a &#34;strong-buy&#34; rating in a research report on Friday, October 31st. Finally, Chardan Capital  reiterated a &#34;buy&#34; rating and issued a $20.00 price objective on shares of Immuneering in a research report on Thursday, November 13th. One analyst  has rated the stock with a Strong Buy rating, six have assigned  a Buy rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $16.50.</p><p><b>Check Out Our Latest Analysis on Immuneering</b></p><h2>Hedge Funds Weigh In On Immuneering</h2><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new stake in shares of  Immuneering during the 1st quarter valued at $32,000.  China Universal Asset Management Co. Ltd. bought a new stake in  Immuneering in the third quarter valued at about $35,000.  Future Financial Wealth Managment LLC acquired a new position in  Immuneering in the third quarter valued at about $35,000.  Kingsview Wealth Management LLC acquired a new position in  Immuneering in the second quarter valued at about $47,000.  Finally, Mercer Global Advisors Inc. ADV bought a new position in  Immuneering during the third quarter worth about $70,000. 67.65% of the stock is owned by institutional investors. </p><h2>About Immuneering</h2> (Get Free Report)<p>Immuneering <span>Nasdaq: IMRX<span></span></span> is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.  </p><p>The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Immuneering</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Executive Order 14330: Trump’s Biggest Yet</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1SWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1SWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Immuneering Right Now?</h2><p>Before you consider Immuneering, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.</p><p>While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IMRX

<p>Immuneering Corporation (NASDAQ:IMRX) insider Leah Neufeld purchased 2,626 shares at $4.15 each, totaling $10,897.90, increasing her stake by 11.25% to 25,970 shares valued at $107,775.50. The acquisition was disclosed to the SEC. The stock rose 4.0% to $4.61, with a market cap of $297.34 million. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average target price of $16.50. Immuneering focuses on AI-driven drug development, with its lead candidate, IRX-2, in Phase 2 trials for diabetic neuropathy.</p>

Immuneering (NASDAQ:IMRX) Insider Acquires $10,897.90 in Stock